RESEARCH REPORT Dave Levitan An international group of experts say that the costs of cancer medications, and those used to treat chronic myeloid leukemia (CML) in particular, have skyrocketed to levels that make treating patients extremely difficult. The group published a perspective piece in the journal Blood online ahead of print on April 25.
A majority of patients on imatinib for treatment of GIST or CML had low or absent levels of osteocalcin, a bone marker secreted by osteoblasts, and about 50% of patients had a decrease in bone mineral density, signaling that long-term treatment may affect bone health in these patients.
CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease.
Contrary to previous laboratory findings, a new study has shown for the first time the effect of stem cell burden on treatment outcome, discovering that tyrosine kinase inhibitors, including imatinib and dasatinib, can rapidly eradicate most chronic myeloid leukemia stem cells.
The European Medicines Agency adopted a “positive opinion” earlier this year regarding conditional marketing approval for bosutinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
As patients and physicians gain experience with a second generation of relatively effective therapies for chronic myeloid leukemia, there is increasing need to quickly understand who will fare best with these drugs.
New research suggests that a novel, investigative drug could help alleviate some of the resistance to tyrosine kinase inhibitor treatment seen in chronic myeloid leukemia (CML). The drug, a pan-BCL2 inhibitor called sabutoclax, could sensitize malignant leukemic stem cells in the bone marrow niche to TKI treatment.
Researchers have identified an enzyme that plays an important role in the reprogramming of malignant progenitor cells in chronic myeloid leukemia. The enzyme, ADAR1, could represent a target for selecting and eradicating leukemia stem cells.
Cell. 2011; 147( 2): 370-381. Kasinski AL,. Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. ... Schwind S,. Maharry K,. Radmacher MD,. et al. Prognostic significance of expression of a single
Questions 1 What are the possible causes of a raised white blood cell count? 2 Given the clinical findings, what is the likely diagnosis? 3 What further investigations should be considered? 4 What are the treatment options? 5 Why might allopurinol be started in this patient?
While chemotherapy and targeted therapy are successful in inducing the remission of myeloidleukemia as acute myeloidleukemia (AML) and chronicmyeloidleukemia (CML), the disease remains largely incurable. This observation is likely due to the drug resistance of leukemic cells, which are responsible for disease relapse. Myeloidleukemia vaccines may most likely be beneficial for eradicating minimal residual disease after treatment with chemotherapy or targeted therapy. Several targeted immunotherapies u
Full Text View. Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute MyeloidLeukemia or Chronic Myelogenous Leukemia. ... Leukemia, Myeloid, Acute. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Full Text View. Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With ChronicMyeloidLeukemia. ... nilotinib. enact. Additional relevant MeSH terms:. Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic,
A hematologically stable CML patient developed a solitary, exquisitely painful ulceration, 7 cm × 5 cm, located on the mid-medial foreleg. There was never any evidence of venous insufficiency. The patient denied the possibility of a spider bite. What is the likely cause of this lesion?
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.